Global autism, neurodiversity & assistive-tech funding — a 2026-27 guide for Indian founders.

Why autism / disability ventures need a different funding map

Three structural reasons.

One, the applicant class is different. A lot of the biggest cheques in autism science — SFARI, OAR, Autism Science Foundation, Eagles Autism Foundation, Autism Speaks’ predoctoral fellowship — are academic research grants that require a PhD/MD faculty PI at an accredited institution. If you are a founder building a product, you are literally not the eligible applicant. You either need an academic co-PI at NIMHANS / AIIMS / IIT / NCBS, or you need to pick a different instrument class (venture funds, accelerators, prizes, impact fellowships).

Two, “autism-relevant” is a much narrower filter than “health-tech”. A pediatric-hospital accelerator that has funded 200 digital-health startups but zero neurodev/AAC ventures is not really an autism funder for you — it is a health-tech funder. In the adversarial pass, several well-known programmes were flagged precisely because their autism relevance is inferred from generic health-tech scope rather than evidenced by named autism-relevant portfolio companies. Those caveats are preserved below.

Three, the “access” question is unusually loaded. For an Indian founder, “can I actually apply from India” splits into five sub-questions:

• Is the programme legally open to Indian-registered entities?
• Does it require US 501(c)(3) status, US bank account, or US residency?
• Does the founder have to relocate (Abu Dhabi’s Hub71, some pediatric-hospital accelerators)?
• Does it require a Delaware C-corp flip or UK Ltd holding structure to receive equity?
• If it is a foreign grant, does it need FCRA routing through an Indian NGO?

Different vehicles impose different combinations. Grant capital (SFARI, OAR, Wellcome, Grand Challenges, Simons, UNICEF Venture Fund’s $100K equity-free) is best when your work has a research angle or open-source public-good angle and you are willing to wait 12–18 months for the first cheque. Equity capital (Autism Impact Fund, Hub71+ Life Sciences, some JLABS-adjacent deals) is best when you have traction, a clear commercial thesis, and either an Indian Pvt Ltd that a foreign VC is comfortable investing in or a flip-ready cap table.

How to read the entries. Each one carries a type tag ([grant] / [fellowship] / [accelerator] / [fund] / [award] / [foundation]), an HQ + delivery-mode note, a specific autism-relevance proof-point (usually a named grantee), the India-eligibility evidence, the cheque size, the next 2026-27 deadline (with UNVERIFIED where the programme has not published one), 2-3 named key people, 3-5 recent portfolio bullets with autism-relevant ones marked with an asterisk (), and a realistic-effort note about what actually gets filtered. Entries with adversarial flags carry a Caveat* box.

Today is July 2026. Deadlines older than that mean the programme is between cycles — treat those as watchlist, not front-of-queue.

1. Autism-explicit funds and foundations

Simons Foundation Autism Research Initiative (SFARI) — New Ideas Award [grant]

HQ / mode: New York, US · remote-friendly (grant to home institution, no relocation)

Why this fits an autism venture: SFARI is the largest private funder of autism science globally, with 550+ funded PIs since 2006. The New Ideas RFA scope is explicitly “study of autism and related neurodevelopmental disorders.” The 2024 Pilot Awards cohort includes Joseph Buxbaum (Seaver Autism Center, Mount Sinai) and Devanand Manoli (UCSF) — both canonical autism-genetics labs.

India eligibility: The RFA FAQ states verbatim: “Yes, foreign institutions may apply.” The only country-level exclusion is China/Hong Kong; India is not excluded. Source: sfari.org/grant/new-ideas-request-for-applications

Cheque: Up to USD 300,000/year for 2 years (USD 600,000 total, inclusive of 20% indirects). Non-dilutive.

Criteria: PI must hold PhD/MD (or equivalent) and a faculty position at an accredited institution — university, medical school, hospital, laboratory, or government research unit. Investigators new to autism explicitly encouraged.

Next 2026-27 deadline: LOIs on rolling basis, opened 29 April 2026. LOI decision within 3–4 months; if invited, full application due within 4 weeks.

Key people: – Kelsey C. Martin, MD, PhD — EVP, SFARI and Neuroscience Collaborations – Jennifer Foss-Feig, PhD — VP and Senior Scientific Officer, SFARI – Alan Packer, PhD — Senior Scientific Officer, SFARI genetics portfolio

Recent portfolio: – 2024 SFARI Pilot Awards cohort — 18 Pilot + 5 Pilot Progression awards, USD 9M+ () – SPARK autism cohort — 50,000+ enrolled families () – Simons Searchlight — global registry across 184 NDD-linked genes, 10,000+ participants (*)

Apply: sfari.org/grant/new-ideas-request-for-applications · via Simons Award Manager

Contact: awards@simonsfoundation.org

Realistic effort: SFARI is the gold standard of autism grants, but you cannot apply as a founder. Route via an Indian faculty co-PI (NIMHANS, NCBS, IISc, AIIMS Neurology/Child Development). The RFA welcomes “investigators new to autism” — meaning an Indian PI with genetics/computational-neuroscience background who has never done autism work before is explicitly in scope, which is genuinely useful.

Caveat (flagged in adversarial review): The India-eligibility evidence rests on inference from the “foreign institutions may apply” clause and the China/HK carve-out — no named Indian grantee institution surfaced in the review. And this is not directly reachable by a founder-as-founder; it is a faculty-PI grant. Treat as “route via an academic partner”, not “apply solo.”

Organization for Autism Research (OAR) — Applied Research Competition [grant]

HQ / mode: Arlington, VA, US · remote-friendly

Why this fits an autism venture: OAR is autism-exclusive by charter. Every Applied Research Grant is autism-focused, with a bias toward practical interventions — ABA services, employment programs, adult transition, family supports. The 2024 cycle awarded 6 grants totalling USD 289,235.

India eligibility: The 2026 RFA explicitly states “International researchers are eligible to apply.” Applicant team must include at least one member with PhD/MD/equivalent affiliated with an accredited institution. Source: researchautism.smapply.org/prog/2026_applied_research_competition

Cheque: Up to USD 50,000 per project for 1–2 years. Up to 9 awards in the 2026-27 cycle. Non-dilutive.

Next 2026-27 deadline: LOI due 16 March 2026 (closed); full proposals due 13 July 2026; grants begin on or after 1 January 2027. If you are reading this after mid-July 2026, watch for the 2027 cycle LOI window opening in Dec 2026.

Key people: – Kristen Essex — Executive Director, OAR (since Dec 2022) – Peter F. Gerhardt, EdD — Chair, Scientific Council (founding chair since 2002) – Joanne Gerenser — Vice-Chair, Scientific Council

Apply: researchautism.smapply.org

Contact: research@researchautism.org

Realistic effort: Same academic-affiliation gate as SFARI — an Indian founder needs a PhD/MD team member at an accredited Indian institution as co-applicant. OAR is more applied than SFARI (interventions, services, transition, employment) so an Ethan-AI-style behaviour-monitoring project with an NIMHANS or Ummeed-affiliated co-PI is well-scoped.

Caveat: International-eligibility language is generic; no named Indian grantee institution surfaced. Route via an accredited Indian academic partner.

Autism Science Foundation — Profound Autism Pilot Grant + Suzanne Wright Accelerator [grant]

HQ / mode: New York, US · remote-friendly

Why this fits: ASF is 100% autism-mandate. The Profound Autism Pilot Grant targets research on individuals with profound autism (co-occurring intellectual disability, minimally verbal) — the most under-funded severity band and directly relevant to any behaviour-monitoring or AAC venture serving the profound cohort.

India eligibility: scientifyRESEARCH listing confirms “applicants may be based anywhere in the world”, subject to affiliation with a university or 501(c)(3)-equivalent institution.

Cheque: – Profound Autism Pilot: USD 35,000 for 1 year, no indirects allowed – Suzanne Wright Memorial Research Accelerator: up to USD 7,500 top-up (existing grant-holders only) – Post-Doctoral S.O.S. Grant: variable

Next 2026-27 deadlines: – Suzanne Wright Accelerator: 6 July 2026 (closed by publication) – Post-Doctoral S.O.S. Grant: October 2026 – Profound Autism Pilot Grants + Pre-doctoral Fellowships: next cycle RFA April 2027, deadline July 2027 – Undergraduate Summer Research Awards: early March 2027

Key people: – Alycia Halladay, PhD — Chief Science Officer – Casey Gold — Director of Operations

Apply: autismsciencefoundation.org/grants-awards-fellowships

Contact: cgold@autismsciencefoundation.org

Realistic effort: Best near-term vehicle here for a 2026-27 cycle is the October 2026 Post-Doctoral S.O.S. Grant if you or a collaborator hold an autism-relevant postdoc profile. Profound Autism Pilot is the more targeted instrument but has a July 2027 next window — long wait.

Caveat: “501(c)(3)-equivalent” is a US tax-status construct that Indian universities do not automatically satisfy without a case-by-case determination. Confirm eligibility with cgold@autismsciencefoundation.org before you invest weeks in a proposal.

Autism Impact Fund (AIF) [fund]

HQ / mode: US (New York, San Francisco, Winter Park FL, Nashville) · rolling, direct equity investment, no relocation

Why this fits: AIF is the single most autism-specific venture fund in the world. Founder Chris Male started it after his son’s autism diagnosis. The entire Fund II thesis is autism, neurodev, behavioural health, and value-based care models — no other VC in this list has a portfolio this concentrated in autism. Named autism-relevant portfolio: Healios (UK, autism/ADHD diagnostics), Genial Care (Brazil, autism care platform), Auticon (Germany, neurodiverse IT consulting), Floreo (VR social skills for autistic learners), SpectrumAi (ABA analytics), Cortica (integrated neurodev care), Jaguar Gene Therapy (genetic autism), BioROSA (blood-based ASD detection).

India eligibility: No explicit India-eligibility statement on the AIF site, and no Indian portfolio company confirmed as of July 2026. However, the fund has actively invested in UK, Germany, and Brazil — demonstrating real non-US appetite. Pitch via team@autismimpact.fund.

Cheque: Equity. $100K minimum, $5M maximum, ~$1.5M sweet spot. Fund II ~$150M AUM, first close April 2026, actively deploying.

Criteria: Fund II priorities are technology and AI-enabled autism care, behavioural / mental-health tools for co-occurring conditions (ADHD, dyslexia, depression, anxiety), and value-based care models. Startups must demonstrably improve outcomes and reduce cost.

Next 2026-27 deadline: Rolling. Fund II actively deploying.

Key people: – Christopher (Chris) Male — Co-Founder & Managing Partner – Brian O’Callaghan — Co-Founder – Robert Sarrazin — CIO & Managing Partner – Ashok Srinivasan — Chief Science Advisor – Nikhita Kulkarni — Associate, Investments & Investor Relations

Apply: autismimpact.fund/contact

Contact: team@autismimpact.fund

Realistic effort: This is the highest-signal autism-vertical VC on the list. For an Indian founder, the practical path is likely a Delaware or Singapore flip-co that AIF can hold equity in — pitching from an India Pvt Ltd works for initial conversations but the cheque usually lands into a US or offshore entity. Their Fund II AI-and-data thesis is directly on-scope for CV+audio behaviour-monitoring plays.

Caveat: India eligibility is unverified (no named Indian portfolio company). Pitch first; expect them to require a flip structure to close.

2. Assistive-tech and disability-tech venture funds

UNICEF Venture Fund (UNICEF Innovation Fund) [fund]

HQ / mode: UNICEF Office of Innovation, NY / Copenhagen · remote-friendly, virtual mentorship, occasional in-person convenings

Why this fits an autism venture: The most tightly on-scope programme in this entire guide for Indian AAC/assistive-tech founders. The UNICEF Venture Fund has run a documented Accessibility / AAC cohort with named autism-relevant portfolio: Ninaad Digital Technology (Pune, India) built Jellow Communicator, a free open-source Android AAC app for non-verbal children — culturally adapted for Indian languages and used across autism, cerebral palsy, and Down syndrome. Also: Yuudee (China, gamified linguistics for autistic children), VRapeutic (Egypt, VR therapy for autism and ADHD), OTTAA Project (Argentina, AI-driven pictogram AAC), Cireha (Argentina, Cboard AAC).

India eligibility: India is an explicit UNICEF programme country. Ninaad received the standard USD 100K equity-free investment — direct proof of Indian-founder access, not inference. Source: unicefventurefund.org/portfolio/ninaad-open-source-application-support-children-speech-impairment

Cheque: Up to USD 100,000 equity-free per startup + product/technology/business mentorship + UNICEF country-office network access + growth-funding pathway. 12-month investment period.

Criteria: For-profit startup registered in a UNICEF programme country (India qualifies), working open-source prototype with real users, frontier tech (AI/ML, XR, blockchain, data science), open-source licensing commitment. Women-led and emerging-market founders explicitly encouraged.

Next 2026-27 deadline: No dedicated Accessibility/AAC cohort call is open as of July 2026 — the previous cohort has graduated. The 2026 calls that ran were Blockchain (closed 10 Mar 2026) and Climate & Health (closed 17 May 2026). Monitor unicef.org/innovation/open-call-applications for the next accessibility call. General rolling applications accepted at unicefventurefund.org/apply-funding but only reviewed against active thematic calls.

Key people: – Thomas Davin — Director, UNICEF Office of Innovation – Sunita Grote — Lead, UNICEF Ventures / Venture Fund

Apply: unicefventurefund.org/apply-funding

Contact: Via site contact form

Realistic effort: This is your highest-fit programme in the entire guide — but only if you can wait for a matching thematic call. The open-source licensing requirement is non-trivial; if your commercial thesis depends on proprietary CV/audio models, you have to be willing to open-source at least the core AAC or accessibility layer. Watchlist priority.

Caveat: No live accessibility/AAC cohort in the 2026-27 window at time of publication. Set a monitor on the Open Calls page and file a general application in the interim.

3. Neurodiversity + mental-health impact VCs

Wellcome Prize for Mental Health Science (with Nature) [award]

HQ / mode: UK (Wellcome, London) · global online submission via Nature portal · fully remote

Why this fits — partially: Prize scope is explicitly depression, anxiety, and psychosis — not autism itself. It fits autism ventures only when the product also directly addresses co-occurring anxiety, depression, or psychosis in autistic populations with clinical-grade evidence and lived-experience input. If you are a pure-play autism screening / AAC / behaviour-monitoring venture, this is the wrong prize — apply to Wellcome Leap FORM (autism-microbiome) instead.

India eligibility: Wellcome’s launch states verbatim: “open for applications from research teams and small and medium-sized organisations worldwide.” PR Newswire India syndication treats it as open to Indian applicants. Source: wellcome.org/insights/articles/wellcome-announces-global-prize-accelerate-new-mental-health-interventions

Cheque: Overall winner USD 1,000,000. Three finalists USD 250,000 each. Total pool USD 1.75M. Non-dilutive, no equity.

Criteria: Research teams and SMEs building evidence-based interventions for depression, anxiety, or psychosis, backed by high-quality research and informed by people with lived experience.

Next 2026-27 deadline: 18 September 2026, 11:59pm UTC. Finalists announced May 2027; winner June 2027.

Key people: – Miranda Wolpert MBE — Director of Mental Health, Wellcome – Magdalena Skipper — Editor-in-Chief, Nature (judging panel co-lead) – Chyrell Bellamy — Yale School of Medicine (panel) – Obi Felten — Flourish Labs (panel)

Apply: go.nature.com/wellcomeprizementalhealth

Realistic effort: For most Ethan-AI-shaped ventures, this is a stretch fit. If your product genuinely delivers anxiety/depression outcomes in autistic children and you have RCT-quality evidence plus autistic co-designers, submit. Otherwise, skip.

Caveat: First cycle — no autism-labelled winners exist yet. Autism relevance is contingent on comorbidity framing. Don’t retrofit an autism pitch as a mental-health pitch; judges will see it.

4. Pediatric and children’s-hospital accelerators

KidsX Accelerator [accelerator]

HQ / mode: US (anchored by Children’s Hospital Los Angeles) · 10-week hybrid virtual programme · no relocation, no visa support, no equity taken

Why this fits: Confirmed autism-relevant alumni: – Floreo (2022 cohort) — VR social/behavioural/communication skills for individuals with ASD; FDA Breakthrough Device () – Embodied / Moxie (2021 inaugural cohort) — social-emotional companion robot piloted with autistic children () – NeuroSigma (2024 cohort) — neurodev/neuromodulation (*)

The 2026 flagship cohort explicitly listed “Pediatric Mental & Behavioral Health” as a focus area — directly on-thesis for CV+audio behaviour-monitoring plays.

India eligibility: Stated policy: “Companies can participate in KidsX accelerators from anywhere in the world.” No confirmed Indian portfolio company as of July 2026 — India eligibility is procedural, not evidenced by a past Indian grantee.

Cheque: No cash. No equity. Value = structured pilot access to 30+ member children’s hospitals + mentorship.

Next 2026-27 deadline: 2027 flagship cohort dates not yet posted. Historically applications open in fall preceding the cohort year — monitor kidsx.health/find-your-innovation-program from Sept–Nov 2026.

Key people: – Omkar Kulkarni — Founder, KidsX (CIO, Children’s Hospital LA) – Rachael Sylora — KidsX program leadership

Apply: kidsx.health/kidsx-accelerator

Contact: kidsx.health@gmail.com

Realistic effort: The prize here is a real pediatric-hospital pilot, not a cheque. If you already have a working prototype and want US clinical validation, this is one of the fastest paths. India-based teams can do the 10-week virtual programme without moving.

Caveat: India eligibility is procedural boilerplate — no named Indian alumnus yet. Between cycles as of July 2026.

Johnson & Johnson Innovation — JLABS (incl. JLABS @ Washington DC embedded at Children’s National) [accelerator]

HQ / mode: US (San Diego, SF, NYC, Washington DC, Shanghai) + virtual EMEA · rolling admissions · no equity, no IP claims

Why this fits: LinusBio — developer of ClearStrand-ASD, the first FDA-Breakthrough hair-strand molecular biomarker for autism — is a documented JLABS NYC alum (*). JLABS @ Washington DC is embedded with Children’s National, whose Center for Autism Spectrum Disorders is the largest pediatric autism program in the DC region.

India eligibility: JLABS EMEA virtual track is explicitly designed so companies can “stay in their home base… no matter where they are in the world.” No confirmed Indian resident as of July 2026 — access is procedural via virtual EMEA.

Cheque: No equity, no IP. Value = subsidised lab space, J&J scientific network, corporate partnerships, mentorship.

Next 2026-27 deadline: Rolling admission via SmApply + periodic themed QuickFire Challenges (recent examples: Urologic Oncology Oct 2025, CAT-PD, Japan Smart Healthy Aging). Monitor jnjinnovation.com/innovation-challenges.

Key people: – Rachel Rath, MBA, MPH — Head of JLABS @ Washington, DC (since Oct 2024)

Apply: jlabsresidency.smapply.io

Contact: jlabs@its.jnj.com

Realistic effort: Ideal if you have life-sciences/diagnostics DNA (LinusBio-style biomarker plays). For pure-software autism ventures, less obviously a fit — you have to convincingly position as digital health with wet-lab or clinical-diagnostic angles.

Caveat: No published 2026-27 flagship deadline (rolling + QuickFire). India access is unevidenced by portfolio.

5. Global health and mental-health innovation funders

Ashoka Fellowship (Global + India) [fellowship]

HQ / mode: US (Arlington VA) with Ashoka India country office · rolling year-round nominations · fully remote (fellow works from home country)

Why this fits: Ashoka has multiple named India-elected autism/disability fellows: – Merry Barua (Ashoka Fellow, elected 2000) — founder of Action for Autism / National Centre for Autism, India’s pioneering autism organisation; drove autism’s inclusion in the Rights of Persons with Disabilities Act 2016. Runs The Open Door school in New Delhi. autism-india.org () – Dr Vibha Krishnamurthy — founder of Ummeed Child Development Center, Mumbai (developmental disability incl. autism). ummeed.org () – Shilpi Kapoor — founder of BarrierBreak (assistive technology). barrierbreak.com () – Thorkil Sonne — Specialisterne (neurodivergent employment across 8 countries) ()

Ashoka also runs a dedicated Disability Systems Change Accelerator (disability.ashoka.org) and the Dela accelerator with IKEA Social Entrepreneurship.

India eligibility: Concretely evidenced by a decades-long track record of Indian fellows and a dedicated Bengaluru country office. This is one of the strongest India-verified entries in the guide.

Cheque: Tailored 3-year living stipend calibrated to local cost of living (paid to the fellow personally, not the org), plus lifetime Ashoka network access, pro-bono services, PR/media support. Non-dilutive.

Criteria: Five criteria — new idea, creativity, entrepreneurial quality, social impact, ethical fibre. Past ideation, working full-time. For-profit and nonprofit both eligible.

Next 2026-27 deadline: Rolling year-round. Each candidate enters a 6–9 month vetting pipeline ending in a global panel.

Key people: – Bill Drayton — Founder & CEO, Ashoka (still active in role as of 2026) – Shruti — Leader, Ashoka South Asia

Apply: ashoka.org/en-us/nominate-fellow

Contact: Nomination form on ashoka.org

Realistic effort: The Ashoka bar is systems-change impact, not MVP-stage traction. If you already have 2–3 years of measurable impact on autism families in India, self-nominate. If you are pre-seed, this is not your first cheque — build to it.

Mulago Foundation — Rainer Arnhold Fellows [fellowship]

HQ / mode: SF, US · in-person retreats (typically Africa or US) · fellows work from home country

Why (partial fit): Mulago is impact-first with a strong India portfolio precedent — five India-based fellows across 2023–25 cohorts: Labhya (mindfulness/SEL in schools), Asan (menstrual cups), Adalat AI (AI for Indian courts), RightWalk Foundation (policy advocacy), Mati Carbon (soil enhancement). The mental-health-for-youth thesis (Shamiri Institute, Friendship Bench, SameSame) is adjacent to autism but not autism-specific.

India eligibility: Hard-confirmed by named portfolio (Labhya, Asan, Adalat AI, RightWalk, Mati Carbon).

Cheque: USD 200,000 (Rainer). Fellows become the exclusive on-ramp to Mulago’s long-term portfolio (multi-year follow-on capital).

Next 2026-27 deadline: 2027 Rainer cohort — sourcing July–October 2026 (active window right now); screening Oct 2026 – Jan 2027; selection early 2027; first retreat Q2 2027.

Key people: – Kevin Starr — CEO – Kristin Gilliss Moyer — COO & Head of Portfolio – Avery Bang — Partner

Apply: mulagofoundation.org/our-fellowships

Realistic effort: The Rainer bar is proven, scalable delivery — early-MVP-stage ventures typically don’t clear it. Mulago’s “impact per dollar” obsession means you must show unit-economics-style delivery numbers.

Caveat: No named autism/neurodev/disability fellow in the current or historical roster. Position this as adjacent (pediatric mental health), not vertical (autism). If autism-vertical is your only story, this is not the right vehicle.

Echoing Green Fellowship [fellowship]

HQ / mode: New York, US · remote-friendly, no relocation

Why (partial fit): The largest early-stage social-founder stipend in the world — USD 100,000 over 18 months. India eligibility is direct (see Shriti Pandey / Strawcture Eco, Mathangi Swaminathan / Parity Lab). But no autism/AAC/neurodiversity-labelled fellow surfaced in the fellow directory — closest disability-adjacent are 2024 Fellows in mobility (Ghana wheelchair devices) and Deaf-community access.

India eligibility: Explicit: “You do not need to be based in the United States or be an American citizen. We encourage applicants of all nationalities, working in any country, to apply.” Named Indian fellows verified.

Cheque: USD 100,000 over 18 months. Non-dilutive for nonprofits; recoverable grant for for-profits.

Next 2026-27 deadline: 2027 cycle not yet posted. 2026 cycle closed Oct 8, 2025. Historically opens Sept–Oct — monitor echoinggreen.org/fellowship/apply.

Key people: – Sharyanne McSwain — President – Cheryl L. Dorsey — CEO (herself a 1992 Echoing Green Fellow)

Realistic effort: Position as social-entrepreneurship not autism-vertical. The judging is generalist impact.

Caveat: No autism/AAC portfolio precedent. Do not treat this as an autism-vertical funder — it’s a broad social-innovation stipend that happens to fund India well.

6. AI-for-Accessibility grants and platform programs

NVIDIA Inception (Healthcare + AI-for-Good track) [accelerator]

HQ / mode: US, fully virtual, rolling year-round · no fees, no equity, no relocation

Why (compute-credit fit, not autism-vertical): NVIDIA Inception has 2,000+ India-based startups per NVIDIA’s own blog. Recent 2026 India joiners include WeAddo (Bengaluru, enterprise healthcare AI, June 2026) and ConnectHealth / Mindbowser (interoperability, March 2026). Membership gets you preferred hardware pricing, cloud compute credits, SDK/model-library access, self-paced technical courses, and Inception Capital Connect investor intros.

India eligibility: Direct — dedicated India portal at nvidia.com/en-in/startups with named 2026 Indian portfolio joiners.

Cheque: No cash, no equity. Value = compute credits + hardware pricing + investor network.

Criteria: Incorporated startup, <10 years old, at least one developer, working website. Excludes consultancies, crypto, cloud providers, resellers, and public companies.

Next 2026-27 deadline: Rolling. Both official pages state: “No deadlines, cohorts, or application fees.”

Apply: programs.nvidia.com/phoenix/application

Contact: inceptionprogram@nvidia.com

Realistic effort: Apply today. This is table-stakes infrastructure for any Indian CV/audio autism-tech venture — free GPU credits materially change your training cost curve. Just don’t pitch this to LPs or partners as “autism-market validation” — it isn’t. It’s compute.

Caveat: Autism-specific portfolio validation is UNVERIFIED — Inception is horizontal AI infrastructure, not a themed accessibility fund. Floreo appears on some external accessibility lists but their public site does not confirm NVIDIA Inception membership.

7. Impact founder fellowships

(Ashoka, Mulago Rainer Arnhold, and Echoing Green are covered in Section 5 above where they naturally cluster. Additional fellowship-style vehicles in Section 8.)

8. Sovereign + national programmes backing autism/disability tech

Hub71+ Life Sciences (Abu Dhabi) [accelerator]

HQ / mode: UAE (Abu Dhabi) · in-person, long-term founder relocation required (Golden Visa route, subsidised housing/office/healthcare)

Why this fits — with a direct autism proof-point: Jade Autism — a gamified cognitive-skills app for children with ASD, developed with autism therapists — is a confirmed Hub71 portfolio company that relocated from Brazil to Abu Dhabi through the programme. Jade Edu extends to ADHD, dyslexia and other neurodivergent conditions; 75,000 family users; Arabic adaptation for MENA. This is a named non-Emirati/non-GCC founder precedent — the closest analogue in the guide to an Indian founder wanting to use Abu Dhabi as an HQ. Source: hub71.com/startups/jade-autism

India eligibility: No nationality restriction on the programme page. Jade Autism (Brazilian founder Ronaldo Cohin relocating from São Paulo to Abu Dhabi) is direct proof-point that non-Emirati founders including Indians can apply, provided one founder commits to Abu Dhabi.

Cheque: AED 250,000 service-provider credits + AED 250,000 cash (SAFE note, dilutive) + optional AED 250,000 top-up on strong programme completion. Total up to AED 750,000 (~USD 204,000).

Criteria: Pre-seed to Series A biotech / medtech / digital health. At least one founder must relocate long-term to Abu Dhabi and build a team from the emirate. 4-round selection: application → founder meeting → partner community evaluation → committee.

Next 2026-27 deadline: – Cohort 19: applications closed 1 Feb 2026, programme starts Sept 2026 – Cohort 20: applications reviewed June–November 2026, programme starts February 2027

Key people: – Ahmad Ali Alwan — CEO, Hub71 – Dr Shaikha Al Mazrouei — Director, Reference National Laboratory, Emirates Drug Establishment (Founding Partner)

Apply: hub71.com/program/hub71-plus-life-sciences/apply

Contact: hub71.com/contact

Realistic effort: This is the single most concrete “relocate to a sovereign hub” option in the guide for an autism founder. Non-negotiable prerequisite: at least one founder physically moves to Abu Dhabi. If that fits your family and team situation, the combination of cash + credits + Golden Visa + MENA market access + Jade Autism precedent is exceptional. If you cannot relocate, do not apply — the commitment gate is real and enforced.

Attvaran Accelerator (AT2030 Programme, GDI Hub / UCL) [accelerator]

HQ / mode: UK-anchored (UCL Global Disability Innovation Hub), India-delivered via IIT Delhi, IIT Madras, and Manush Labs · hybrid, Delhi-based in-person components

Why this fits — extremely strong India+autism fit: Attvaran is one of the few programmes globally that is simultaneously autism-relevant AND India-native. Cohort 1 (July 2024) included named Indian autism ventures: – Ai.gnosis / Aignosis — 5-minute ₹700 AI autism screening test, B2B with 250+ medical centres; Shark Tank India S4 (₹1 Cr for 8% equity) () – Insighte — personalised therapy platform for children with autism and ADHD across home, school, online ()

Phase 2 (Nov 2024 announcement) expanded to 50 disability-inclusion startups. Sources: ucl.ac.uk/news/2024/nov/ucl-and-indian-partners-announce-new-round-funding-50-disability-inclusion-startups · at2030.org/attvaran

India eligibility: Not just eligible — this programme is built for Indian-registered startups.

Cheque: Non-dilutive seed grant (amount undisclosed) + 3–6 month accelerator with IIT lab access, mentorship, investor demo day, no equity.

Criteria: Early-stage assistive tech (Spark/Start/Scale tracks). Must address a critical problem for people with disability or elderly; Asia-focused; past ideation.

Next 2026-27 deadline: UNVERIFIED. Phase 2 (50 startups, Nov 2024) is executing through 2025–26; the at2030.org/attvaran “Apply now” link is live but no window is shown. Email info@disabilityinnovation.com directly to confirm current window.

Key people: – Tigmanshu Bhatnagar — Attvaran Accelerator Lead, GDI Hub / UCL – Prof Catherine (Cathy) Holloway — Academic Director, GDI Hub – Manush Labs — India delivery partner

Apply: at2030.org/attvaran

Contact: info@disabilityinnovation.com

Realistic effort: Highest-priority Indian-delivered autism/assistive-tech programme in this guide. Even without a confirmed open cycle, email the programme lead — if there is any way to be in the queue for the next intake, it is worth the outreach.

Caveat: No public 2026-27 application window confirmed as of publication — treat as watchlist, not front-of-queue apply, until GDI Hub responds.

9. Family foundations for neuroscience + mental health + autism

Simons Foundation Autism and Neuroscience Conferences and Courses Awards [grant]

HQ / mode: New York, US · funds an autism/neuroscience conference or course hosted by an Indian institution Sept 2026 – Aug 2029

Why this fits: This is the vehicle for Indian universities / hospitals / nonprofits that want to host an autism training program, clinician-scientist course, or researcher conference. SFARI (autism arm) is one of four eligible initiatives.

India eligibility: No citizenship requirements; only country-level exclusion is China/Hong Kong. Indian universities, hospitals, and nonprofits are eligible institutional applicants.

Cheque: Variable, funds a portion of conference/course costs. Requests above USD 25,000/year need strong justification. Gift structure, no indirects, multiple co-funders encouraged.

Next 2026-27 deadline: Current cycle closed (LOI April 15, 2026; full proposals July 8, 2026; awards start Sept 1, 2026). Next cycle expected early 2027 for events in the Sept 2027–Aug 2029 window.

Apply: simonsfoundation.org/grant/simons-foundation-autism-neuroscience-conferences-and-courses-awards

Contact: awards@simonsfoundation.org

Realistic effort: Not a founder-reachable vehicle. If you run an NGO, therapy centre, or academic-adjacent institution and want to host an autism training summit or clinician course in India, this is a straightforward fit. If you are a for-profit product startup, wrong instrument.

Caveat: Restricted to nonprofits, universities, hospitals, labs, government agencies. Not for for-profit startups.

Autism Speaks — Predoctoral Fellowship for Autistic Scientists [fellowship]

HQ / mode: US · remote-friendly (fellowship supports research at applicant’s home doctoral institution)

Why (narrow fit): Explicitly designed for autistic doctoral students conducting autism research at US or international institutions. Autism Speaks also runs the Global Autism Public Health Initiative (GAPH) in 70+ countries.

India eligibility: Open to autistic doctoral students at US and international institutions per the autismspeaks.org/research-grants page. Indian PhD programs (PhD, ScD, MD/PhD) qualify.

Cheque: USD 40,000/year × 2 years = USD 80,000 total (USD 28k stipend + USD 12k research allowance annually). Non-dilutive.

Criteria: Applicant must self-identify as autistic AND be enrolled in a research doctoral program with ≥2 years remaining.

Next 2026-27 deadline: LOI 5 Aug 2026 (8pm ET); full application 23 Sept 2026; fellowship start 1 April 2027. Informational webinar 30 June 2026.

Key people: – Keith Wargo — President & CEO, Autism Speaks – Andy Shih, PhD — Chief Science Officer

Apply: autismspeaks.org/research-grants

Contact: grantadmin@autismspeaks.org

Realistic effort: Wrong instrument if you are a founder building a product. Right instrument if you are an autistic Indian PhD student researching autism — in which case, apply.

Caveat: Requires personal autism self-identification AND doctoral enrolment. Founder audience is not the applicant class.

10. UN and humanitarian tech programmes

Covered above under Section 2 (UNICEF Venture Fund) which is the single strongest UN-humanitarian vehicle on this map for Indian AAC/assistive-tech ventures.

What to watch out for, what to sequence, and how to actually get money

Pay-to-play patterns

If you Google “autism awards 2026” you will find a dozen slick-looking directories that will happily invoice you USD 500–5,000 for a “recognition” plaque, a magazine feature, or a paid listing in a “Top 10 Autism Startups” advertorial. Signals to avoid:

• Any “award” that asks for a nomination fee, application fee, or “processing charge”
• Any “founder magazine” recognition where the primary deliverable is a PR write-up you pay to publish
• Any “global summit” that requires a paid delegate ticket to be “considered for the award”
• Any programme where the selection panel and the media property share the same commercial owner
• Any list-and-directory site aggregating “grants” that redirects you to a paid course, coaching product, or subscription

Every single programme in this guide is free to apply and none charges a nomination fee. If you find a “Global Autism Innovation Award 2026” that asks you to pay to be considered — it is not on this list for a reason.

Grant capital vs equity capital for autism ventures

Grant capital (SFARI, OAR, ASF, Wellcome, Simons Conferences, UNICEF Venture Fund equity-free, Attvaran, Ashoka stipend) is best when: your work is research-adjacent or has an open-source public-good angle; you can wait 6–18 months for first cheque; you don’t want dilution; you are willing to route via an academic PI, an FCRA-registered Indian NGO, or an institutional host. Grant capital is slow, non-recurring, and often restricted in what you can spend it on — but it is the right first cheque for most autism-vertical work in India.

Equity capital (Autism Impact Fund, Hub71+ Life Sciences, NVIDIA Inception’s Capital Connect intros, JLABS network intros) is best when: you have working product with real users; a commercial thesis a VC can underwrite; and either a foreign holding structure or a willingness to build one. Equity is faster, larger, and comes with pressure to scale on a US or global timeline that may not match therapy-services unit economics in India.

CSR-eligible corporate philanthropy is a third capital stack most foreign-focused guides ignore. Indian corporates under the Companies Act 2013 must spend 2% of average net profit on CSR, and health/education/differently-abled projects qualify. If your Indian delivery arm is a Section 8 company, Trust, or Society and you can produce Form CSR-1 registration, you can accept CSR grants — a category that has more money flowing through it in India than most global VC funds combined.

The FCRA question

If you are routing foreign grant money (SFARI, OAR, Wellcome, ASF, Simons Foundation, UNICEF, Eagles Autism Foundation) through an Indian nonprofit, that nonprofit must be FCRA-registered with the Ministry of Home Affairs. FCRA registration takes 6–12 months and requires the entity to be at least 3 years old with proof of activity in its charitable purpose and audited financials showing at least ₹15 lakh spent over the prior 3 years on the stated cause.

Practical implication: if you don’t already have an FCRA-registered NGO, you cannot receive foreign grants directly to your Indian nonprofit. Workarounds are (a) partner with an existing FCRA-registered organisation (Action for Autism, Ummeed, and similar established institutions are the natural options), (b) receive the grant into a US or UK 501(c)(3)-equivalent fiscal sponsor and disburse services rather than cash, or (c) receive grants only in your for-profit entity, which doesn’t need FCRA but changes the tax treatment.

Delaware flip vs India Pvt Ltd vs UK Ltd

• India Pvt Ltd — cheapest to set up, easiest domestic operations, easiest CSR eligibility once you also have a Section 8 or Trust sister-org. Weakness: foreign VCs (especially US ones like AIF) generally do not invest directly into Indian Pvt Ltds without a holding-structure workaround.
• Delaware C-corp with Indian Pvt Ltd subsidiary — the standard “flip” structure for Indian startups raising US venture. Enables US VC investment cleanly. Weakness: RBI compliance is real, US tax filing is real, and once flipped it is hard to unflip if you later want to raise domestic capital or list in India.
• Singapore Pte Ltd — increasingly the middle path. Recognised by US, UK, and Middle East investors; simpler tax treaty with India than Delaware; often preferred by Southeast Asia + Middle East LPs including sovereign-adjacent capital from UAE.
• UK Ltd — best when your investor base is UK-centric (Wellcome grantees, GDI Hub connections). Modest overhead.

For a founder-stage autism venture applying to programmes in this guide, the practical recommendation is: run your Indian Pvt Ltd normally; do not flip until a specific VC term-sheet triggers the need; if you need a foreign holding entity for grant receipt (e.g., a fiscal sponsor for US foundations), route through an established US/UK fiscal sponsor rather than setting up an offshore entity of your own.

Realistic timelines and rejection rates

• Research grants (SFARI New Ideas, OAR, ASF): 3–4 months from LOI to LOI decision; another 4 weeks to full proposal; another 3–6 months to award. Total: 8–14 months to first cheque if you win. Acceptance rate: 5–15%.
• Fellowships (Ashoka, Echoing Green, Mulago Rainer): 6–9 months from nomination/application to decision. Acceptance rate: 1–5%. Ashoka is closer to 1%.
• Prizes (Wellcome Prize for Mental Health Science): 6–8 months from application to finalist announcement; 9–10 months to winner. Single-digit acceptance.
• Equity accelerators (Hub71, KidsX, JLABS): 3–6 months from application to programme start. Acceptance rates vary widely (5–30% depending on stage of programme and thematic fit).
• VC direct (AIF, others): 2–4 months from first meeting to term sheet if there is fit; another 2–3 months to close.
• UNICEF Venture Fund: 2–4 months from cohort call to cohort selection; 12-month investment period.

Rule of thumb: assume 12 months from “I decide to apply” to “money in the bank” for any single grant, and 3 rejections for every 1 award. Which means you need to be running 4–6 applications in parallel to have any chance of a real capital stack in 2026-27.

How to sequence

1. Immediately (July 2026): Apply to NVIDIA Inception (rolling, free, compute credits are meaningful). Email GDI Hub about Attvaran. Pitch AIF via team@autismimpact.fund even if you’re not ready — the relationship compounds. If you have a working open-source AAC prototype, file a general UNICEF Venture Fund application and set a monitor for the next Accessibility cohort call.
2. August–September 2026: If autism-relevant mental-health comorbidity is a real angle for you, apply to the Wellcome Prize (deadline 18 Sept 2026). If you can build an academic co-PI relationship at an Indian institution, start drafting the SFARI LOI.
3. Q4 2026: Watch for the 2027 Echoing Green cycle (typically opens Sept–Oct). Watch for KidsX 2027 flagship announcement. If Hub71 Cohort 20 is on your table and you can commit to Abu Dhabi relocation, apply during the June–November review window.
4. Q1 2027: OAR Applied Research Competition LOI window reopens (historically December–March). SFARI Conferences and Courses next cycle (early 2027). ASF Profound Autism Pilot next cycle (April–July 2027).
5. Continuous: Ashoka Fellowship, AIF pitch, Mulago Rainer sourcing (July–October each year), UNICEF Venture Fund general rolling pool.

Do not sequence serially. Sequence parallel — file 4–6 in flight always, expect most to be rejected, treat each application as building the next one.

Companion resource

For domestic funding (Indian government, Startup India, Section 8 co, CSR mechanics, FCRA specifics, and Indian family offices), see the companion article at ethanai.in/funding-autism-special-needs-india/. The two guides are meant to be read together — most Indian autism founders will build a capital stack that mixes both.

Get in touch

If you spotted a programme that belongs on this list — especially one with a named Indian autism/AAC/neurodiversity grantee we missed — or if you want to compare notes on a specific application, write to hello@ethanai.in or ping Pratush Charan on LinkedIn. This guide is updated as programmes reopen cycles; corrections and additions from founders in the trenches are the fastest way it stays useful.